202 related articles for article (PubMed ID: 11290432)
1. Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse.
Alexandre J; Fizazi K; Mahé C; Culine S; Droz JP; Théodore C; Terrier-Lacombe MJ
Eur J Cancer; 2001 Mar; 37(5):576-82. PubMed ID: 11290432
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Risk-adapted Surveillance vs Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer: A Retrospective Follow-up Study of 81 Patients.
Fan G; Zhang L; Yi L; Jiang ZQ; Ke Y; Wang XS; Xiong YY; Han WQ; Zhou X; Liu C; Yu X
Asian Pac J Cancer Prev; 2015; 16(8):3267-72. PubMed ID: 25921130
[TBL] [Abstract][Full Text] [Related]
3. Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors.
Li X; Guo S; Wu Z; Dong P; Li Y; Zhang Z; Yao K; Han H; Qin Z; Zhou F; Liu Z
World J Urol; 2015 Sep; 33(9):1351-7. PubMed ID: 25471669
[TBL] [Abstract][Full Text] [Related]
4. Detailed pathologic analysis on the co-occurrence of non-seminomatous germ cell tumor subtypes in matched orchiectomy and retroperitoneal lymph node dissections.
Spratt DE; Suresh K; Osawa T; Schipper M; Jackson WC; Abugharib A; Lebastchi A; Smith D; Montgomery JS; Palapattu GS; Priya Kunju L; Wu A; Lew M; Tomlins SA; Chinnaiyan AM; Weizer AZ; Hafez KS; Kaffenberger SD; Udager A; Mehra R
Med Oncol; 2018 Jan; 35(3):21. PubMed ID: 29387987
[TBL] [Abstract][Full Text] [Related]
5. Long-term clinical outcome in patients with stage-I nonseminomatous germ cell cancer. A critical review of own treatment modalities in a retrospective study.
Seseke S; Bierwirth S; Strauss A; Ringert RH; Seseke F
Int Braz J Urol; 2008; 34(6):715-22; discussion 723-4. PubMed ID: 19111076
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors.
Gumus M; Bilici A; Odabas H; Ustaalioglu BBO; Kandemir N; Demirci U; Cihan S; Bayoglu IV; Ozturk T; Turkmen E; Urakci Z; Seker MM; Gunaydin Y; Selcukbiricik F; Turan N; Sevinc A
World J Urol; 2017 Jul; 35(7):1103-1110. PubMed ID: 27812752
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer.
Studer UE; Fey MF; Calderoni A; Kraft R; Mazzucchelli L; Sonntag RW
Eur Urol; 1993; 23(4):444-9. PubMed ID: 7687549
[TBL] [Abstract][Full Text] [Related]
8. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
[No Abstract] [Full Text] [Related]
9. Risk-adapted management for patients with clinical stage I non-seminomatous germ cell tumour of the testis.
Guney S; Guney N; Sonmez NC; Ergenekon E
Med Oncol; 2009; 26(2):136-42. PubMed ID: 18821067
[TBL] [Abstract][Full Text] [Related]
10. Adult primary pure teratoma of the testis. The Indiana experience.
Leibovitch I; Foster RS; Ulbright TM; Donohue JP
Cancer; 1995 May; 75(9):2244-50. PubMed ID: 7712432
[TBL] [Abstract][Full Text] [Related]
11. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy.
Heidenreich A; Pfister D
Arch Esp Urol; 2012 Mar; 65(2):215-26. PubMed ID: 22414450
[TBL] [Abstract][Full Text] [Related]
12. A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion.
Lago-Hernandez CA; Feldman H; O'Donnell E; Mahal BA; Perez V; Howard S; Rosenthal M; Cheng SC; Nguyen PL; Beard C; D'Amico AV; Sweeney CJ
Ann Oncol; 2015 Jul; 26(7):1396-401. PubMed ID: 25888612
[TBL] [Abstract][Full Text] [Related]
13. Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis.
Amato RJ; Ro JY; Ayala AG; Swanson DA
Urology; 2004 Jan; 63(1):144-8; discussion 148-9. PubMed ID: 14751368
[TBL] [Abstract][Full Text] [Related]
14. Results of the surveillance policy of stage I non-seminomatous germ cell testicular tumours.
Colls BM; Harvey VJ; Skelton L; Thompson PI; Dady PJ; Forgeson GV; Perez DJ
Br J Urol; 1992 Oct; 70(4):423-8. PubMed ID: 1333336
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group.
Klepp O; Olsson AM; Henrikson H; Aass N; Dahl O; Stenwig AE; Persson BE; Cavallin-Ståhl E; Fosså SD; Wahlqvist L
J Clin Oncol; 1990 Mar; 8(3):509-18. PubMed ID: 1689773
[TBL] [Abstract][Full Text] [Related]
16. Is modified retroperitoneal lymph node dissection alive for clinical stage I non-seminomatous germ cell testicular tumor?
Basiri A; Ghaed MA; Simforoosh N; Tabibi A; Danesh A; Nouralizadeh A; Parizi MK
Urol J; 2013; 10(2):873-7. PubMed ID: 23801470
[TBL] [Abstract][Full Text] [Related]
17. Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer.
Klepp O; Dahl O; Flodgren P; Stierner U; Olsson AM; Oldbring J; Nilsson S; Daehlin L; Tørnblom M; Småland R; Starkhammar H; Abramsson L; Wist E; Raabe N; Edekling T; Cavallin-Ståhl E
Eur J Cancer; 1997 Jun; 33(7):1038-44. PubMed ID: 9376184
[TBL] [Abstract][Full Text] [Related]
18. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
[TBL] [Abstract][Full Text] [Related]
19. An analysis of surveillance for stage I combined teratoma--seminoma of the testis.
Thomas R; Dearnaley D; Nicholls J; Norman A; Sampson S; Horwich A
Br J Cancer; 1996 Jul; 74(1):59-62. PubMed ID: 8679458
[TBL] [Abstract][Full Text] [Related]
20. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
